Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Melanoma, Cutaneous Malignant × nintedanib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 16 Ovarian Neoplasms 7 Neoplasms 6 Colorectal Neoplasms 4 Recurrence 3 Prostatic Neoplasms 3 Carcinoma, Hepatocellular 3 Breast Neoplasms 3 Uterine Cervical Neoplasms 2 Radiation Pneumonitis 2 Peritoneal Neoplasms 2 Mesothelioma, Malignant 2 Lung Neoplasms 2 Leukemia, Myeloid, Acute 2 Glioblastoma 2 Fallopian Tube Neoplasms 2 Thyroid Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumors 1 Small Cell Lung Carcinoma 1 Sarcoma 1 Rectal Neoplasms 1 Patients With Any Advanced Solid Tumors 1 Ovarian Diseases 1 Oligodendroglioma 1 Neoplasms by Site 1 Neoplasm Metastasis 1 Mesothelioma 1 Melanoma, Cutaneous Malignant 1 Malignant Solid Tumour 1

Interventions

pembrolizumab 2 nintedanib 1 dabrafenib 1 Vitamin D 1 Surveys and Questionnaires 1 Paclitaxel 1 Eye Movement Desensitization Reprocessing 1 Electrochemotherapy 1 Cholecalciferol 1 Biopsy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02308553 2020-10-14

NIPAWILMA

University Hospital, Essen

Phase 1/2 Completed

Melanoma, Cutaneous Malignant

Data powered by HemOnc (CC BY 4.0) Colophon ⚡